Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

bleomycin

DBL BLEOMYCIN SULFATE

bleomycin (DBL BLEOMYCIN SULFATE) is an FDA-listed pharmaceutical active ingredient. Associated with Pfizer Australia Pty Ltd.

TGA: approved NMPA: clinical trials
Patents linked 7
Pipeline programs 12
News articles 0
Drug details — bleomycin
Class
—
Route
—
Patents
7
Programs
12
Data quality
0.81
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

bleomycin (DBL BLEOMYCIN SULFATE) is an FDA-listed pharmaceutical active ingredient. Associated with Pfizer Australia Pty Ltd.

Key facts

INN bleomycin
Brand DBL BLEOMYCIN SULFATE
Originator Pfizer Australia Pty Ltd

Approval history

Authority Status Date
TGA approved —
NMPA clinical trials —

Pipeline programs

Browse pipeline Sponsor programs
  1. C25003 Phase 3 · Takeda · Advanced Classical Hodgkin Lymphoma
  2. Medpulser Electroporation with Bleomycin Phase 3 · INOVIO Pharmaceuticals · Head Neck Cancer
  3. BLEOMYCIN Phase 2 · Telethon Foundation · colorectal cancer
  4. BLEOMYCIN, CISPLATIN Phase 2 · Telethon Foundation · patients with newly diagnosed or recurrent high-grade or ini
  5. Bleomycin Phase 2 · Chinese Academy of · Lymphatic Malformation
  6. Bleomycin medac, 15 000 RÜ süstelahuse pulber Phase 2 · George Institute for · VASCULAR MALFORMATION
  7. MK-3475-667 Phase 2 · MSD Merck Sharp · Classical Hodgkin lymphoma in children and young adults
  8. bleomycin sulfate Phase 2 · Shanghai Medical College · Childhood Germ Cell Tumor

Related patents

Browse patents Pfizer Australia Pty Ltd patent hub

  1. US 12251561

    Minimally invasive dermal electroporation device

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11565107

    Tolerable and minimally invasive skin electroporation device

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11291836

    Minimally invasive dermal electroporation device

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10668279

    Miniminally invasive dermal electroporation device

    Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9034313

    Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same

    Expires Mon May 14 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7931640

    Method for muscle delivery of drugs, nucleic acids and other compounds

    Expires Mon Apr 21 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 6610044

    Method for genetic immunization

    Expires Mon Aug 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is bleomycin?

bleomycin (DBL BLEOMYCIN SULFATE) is an FDA-listed pharmaceutical active ingredient. Associated with Pfizer Australia Pty Ltd.

What is the brand name for bleomycin?

DBL BLEOMYCIN SULFATE is a marketed brand name for bleomycin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.